https://www.oaepublish.com/articles/2394-5079.2022.58
Immunotherapy biomarkers for HCC: contemporary challenges and emerging opportunities
Immune checkpoint inhibitor regimens are the standard of care for systemic treatment of advanced, unresectable, or metastatic HCC for the foreseeable future.
immunotherapy biomarkershcccontemporarychallengesemerging
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.809971/full
Frontiers | Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for...
Purpose: Mismatch repair deficient (dMMR) is an established biomarker for the response to the programmed cell death (PD)-1 inhibitors in metastatic colorecta...